Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphosys Ag (MOR)
NASDAQ:MOR
Morphosys Ag (MOR) Stock Price & Analysis
238 Followers
MOR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.19 - $18.31
Previous Close$17.87
Volume458.75K
Average Volume (3M)1.83M
Market Cap
$2.67B
Enterprise Value$2.78B
Total Cash (Recent Filing)€158.50M
Total Debt (Recent Filing)€256.45M
Price to Earnings (P/E)-5.2
Beta0.82
Next Earnings
Aug 07, 2024EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding150,620,548
10 Day Avg. Volume843,787
30 Day Avg. Volume1,831,691
Standard Deviation0.17
R-Squared0.12
Alpha-0.00434
Financial Highlights & Ratios
Price to Book (P/B)-2.30
Price to Sales (P/S)11.30
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$18.25Price Target Upside2.01% Upside
Rating ConsensusHold
Number of Analyst Covering3
Morphosys Ag News
PremiumCompany Announcements
MorphoSys AG Announces Major Voting Rights Shift
PremiumCompany Announcements
MorphoSys AG Announces Major Voting Rights Changes
PremiumCompany Announcements
MorphoSys AG Reports Shift in Major Holdings
PremiumCompany Announcements
MorphoSys Announces Barclays PLC’s Voting Rights Shift
PremiumCompany Announcements
MorphoSys AG Reports Shift in Major HoldingsPremiumCompany Announcements
Barclays PLC Acquires 10% Stake in MorphoSys AG
PremiumCompany Announcements
MorphoSys AG Navigates Takeover and Asset Sale
Bulls Say, Bears Say
Bulls Say
Acquisition ProgressNVS' acquisition of MOR is on track to close which provides clarity to investors.
Strategic Fit And CommercializationAcquisition by Novartis provides opportunity to maximize pelabresib's potential.
Therapeutic DevelopmentResults from Phase 3 MANIFEST-2 demonstrated clear benefits in myelofibrosis, notably in spleen size reduction.
Bears Say
Analyst RatingThe analyst downgrades the stock to Equal Weight, suggesting limited upside potential from the current price.
Analyst Rating ChangeRating lowered to Market Perform from Market Outperform on MorphoSys.
Negotiation UncertaintyThere is no certainty negotiations will conclude successfully.
---
Ownership Overview
0.00%
Insiders
3.29% Mutual Funds
0.74% Other Institutional Investors
95.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MOR FAQ
What was Morphosys Ag’s price range in the past 12 months?
Morphosys Ag lowest stock price was $4.18 and its highest was $18.30 in the past 12 months.
What is Morphosys Ag’s market cap?
Currently, no data Available
When is Morphosys Ag’s upcoming earnings report date?
Morphosys Ag’s upcoming earnings report date is Aug 07, 2024 which is in 90 days.
How were Morphosys Ag’s earnings last quarter?
Morphosys Ag released its earnings results on Apr 29, 2024. The company reported -$2.211 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$1.912.
Is Morphosys Ag overvalued?
According to Wall Street analysts Morphosys Ag’s price is currently Undervalued.
Does Morphosys Ag pay dividends?
Morphosys Ag does not currently pay dividends.
What is Morphosys Ag’s EPS estimate?
Morphosys Ag’s EPS estimate is -$0.54.
How many shares outstanding does Morphosys Ag have?
Morphosys Ag has 150,865,690 shares outstanding.
What happened to Morphosys Ag’s price movement after its last earnings report?
Morphosys Ag reported an EPS of -$2.211 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went up 0.288%.
Which hedge fund is a major shareholder of Morphosys Ag?
Among the largest hedge funds holding Morphosys Ag’s share is EntryPoint Capital, LLC. It holds Morphosys Ag’s shares valued at 228K.
---
Morphosys Ag Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$18.25 (2.01% Upside)
$18.25 (2.01% Upside)
Blogger Sentiment
Bullish
MOR Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
242.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.34%
Trailing 12-Months
Company Description
Morphosys Ag
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. It operates through the Proprietary Development and Partnered Discovery segments. The Proprietary Development segment combines proprietary research and development of therapeutic compounds. The Partnered Discovery segment offers technologies to make human antibody-based therapeutics on behalf of partners in the pharmaceutical industry. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
---
MOR Company Deck
---
MOR Earnings Call
Q4 2024
0:00 / 0:00
---
MOR Stock 12 Month Forecast
Average Price Target
$18.25
▲(2.01% Upside)
Technical Analysis
Best Analysts Covering MOR
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
+11.25%
reiterated a buy rating 5 months ago
Copying James Gordon's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.25% per trade.
---